Melissa Wasserstein
Clinical Biochemical Genetics · New York, NYNPI 1023066198
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 91.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $30,971 and has fallen 78.6% since, to $6,631 in 2025.
Across 97 payments — averaging $1458.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$129K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Sanofi-aventis U.S. LLC$4K
- Shire North American Group Inc$3K
- PTC Therapeutics, Inc.$176
- Biomarin Pharmaceutical Inc.$159
- plus $146 from 3 others
Across 125 payments — averaging $21,796 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$2.3M
- AstraZeneca$220K
- Takeda Pharmaceuticals U.S.A., Inc.$169K
- Ultragenyx Pharmaceutical Inc.$35K
What the payments were for
- Consulting fees$81,31557%
- Speaking & faculty fees$52,88437%
- Travel & lodging$6,1204%
- Food & beverage$1,0301%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 82 | $129,072 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $4,775 |
| Sanofi-aventis U.S. LLC | 2 | $4,166 |
| Shire North American Group Inc | 2 | $2,956 |
| PTC Therapeutics, Inc. | 3 | $176 |
| Biomarin Pharmaceutical Inc. | 3 | $159 |
| Travere Therapeutics, Inc. | 1 | $71 |
| Amicus Therapeutics, Inc. | 1 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XENPOZYME$47,280
- ALDURAZYME$16,384
- OLIPUDASE ALFA$6,929
- ELAPRASE$2,800
- NO PRODUCT DISCUSSED$2,646
How this compares
Too few clinical biochemical genetics providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DojolviTriheptanoin | 11 | $336,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ultragenyx Pharmaceutical Inc.Dojolvi | $30 | $336,13111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical biochemical genetics providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other clinical biochemical genetics in New York
- Gustavo MaegawaNew York$43K
- Paul LevyBronx$295
- Natasha ShurAlbany$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.